ID_Journal/Patent	**Doi/PMID**	**Table/Figure**	**Tested compound**	**Assay**			P	R	O	T	O	C	O	L
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374			Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions										
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg37	**T3**	Doxil	**Patient characteristics and Doxil dose according to reaction status**			**Induced protocol**				**Tested compound**			
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**					**Animal status**		Conscious				**Name**	Doxil (pegylated liposomal doxorubicin)
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**			Non-reactors	Grade 2 or 3 reactors							**Vehicle**	5% Dextrose (250mL)
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**			(n=16)	(n=13)	**Biological material**			Whole organism			**Treatment type**	Acute
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**		Age	41-73	38-77		**Organism**		Animal			Period:	
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**		Number of males	7	6			**Species**	Human			Frequency:	
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**		Total doxil dose (mg)	40-146	40-306			**Strain**				**Administration**	Unique
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**		Initial dose rate (mg/min)	0.13-0.49	0.13-1.02			**Sex**	Either			**Admin. Type**	Intravenous
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**							**Development**				**Comment**	infused over 1h
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**							**Age**		**Other compound**			
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**							**Weight**				**Name**	
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**							**Genotype**				**Vehicle**	
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**							**Phenotype**				**Treatment type**	
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**							**Feeding/drinking**				Period:	
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**							**State**	variety of tumors; not premedicated with steroids or antihistamines			Frequency:	
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**							**Surgery**				**Administration**	
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**						**Comment**					**Admin. Type**	
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**											**Comment**	
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**									**Inductive agent**			
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**											**Name**	
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**											**Vehicle**	
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**											**Treatment type**	
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**											Period:	
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**											Frequency:	
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**											**Administration**	
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**											**Admin. Type**	
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**											**Comment**	
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**									**Parameters of the biological response**			
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**									**Start time**			Following the start of infusion
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**									**Duration**			30 min
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**									**Measure Type**			
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**									**Measure Object**			Grade of hypersensitivity symptoms (0-4)
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**									**Analysis**			Visual observation
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**									**Statistical test**			
http://annonc.oxfordjournals.org/content/14/9/1430.full.pdf+html	10.1093/annonc/mdg374	**T3**									**Comment**			